WebIn a major announcement today, Zelira Therapeutics has secured a significant US$8.6 million investment to advance its HOPE® autism trials. US-based… Shared by Rahul … Web26 mei 2024 · Thomas joined Zelira two years ago with more than 20 years’ of experience across academia, research governance and government health policy work. “Australian …
Argenica Therapeutics secures experienced professional to lead …
WebZelira® Therapeutics Ltd Authors Dr Meghan Thomas Vice President Clinical Programs and Operations, Zelira Therapeutics, Perth, Australia Prof Christopher Frampton Department … Web5 apr. 2024 · On 10 January 2024, Zelira announced it had received $250,000 of the $1,000,000 upfront, non-refundable, non-contingent licensing fee from DRCN. Zelira had been advised the balance of the $750,000 would be paid in third quarter of fiscal year 2024. inter city rail brisbane
Dr. Oludare Odumosu of Zelira Therapeutics: - Medium
Web23 feb. 2024 · Zelira is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain as well as offering over-the- counter (OTC) products. Web31 dec. 2024 · ZELIRA THERAPEUTICS LIMITED Applicable security for the reorganisation Trading in the post consolidation or split +securities commences on a deferred settlement basis 14/4/2024 Record Date 19/4/2024 Issue Date 27/4/2024 Notification of Consolidation/Split 1 / 8 Notification of Consolidation/Split Refer to below for full details of … Web14 nov. 2024 · ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled. 08/09/2024. Partial Receipt of Health House Loan. 07/09/2024. Investor Briefing Webinar Presentation. 06/09/2024. Investor Briefing Webinar Details. 31/08/2024. Zelira Full Year Results. inter city rail chicago schedule